|
1
|
van Westrhenen R, van Schaik RHN, van
Gelder T, Birkenhager TK, Bakker PR, Houwink EJF, Bet PM,
Hoogendijk WJG and van Weelden-Hulshof MJM: Policy and practice
review: A first guideline on the use of pharmacogenetics in
clinical psychiatric practice. Front Pharmacol.
12(640032)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Moncrieff J and Kirsch I: Efficacy of
antidepressants in adults. BMJ. 331:155–157. 2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Mitchell AJ: Depressed patients and
treatment adherence. Lancet. 367:2041–2043. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sawada N, Uchida H, Suzuki T, Watanabe K,
Kikuchi T, Handa T and Kashima H: Persistence and compliance to
antidepressant treatment in patients with depression: A chart
review. BMC Psychiatry. 9(38)2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
van Westrhenen R, Aitchison KJ,
Ingelman-Sundberg M and Jukić MM: Pharmacogenomics of
antidepressant and antipsychotic treatment: How far have we got and
where are we going? Front Psychiatry. 11(94)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Altar CA, Carhart J, Allen JD, Hall-Flavin
D, Winner J and Dechairo B: Clinical utility of combinatorial
Pharmacogenomics-guided antidepressant therapy: Evidence from three
clinical studies. Mol Neuropsychiatry. 1:145–155. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhou Y, Ingelman-Sundberg M and Lauschke
VM: Worldwide distribution of cytochrome P450 alleles: A
Meta-analysis of Population-scale sequencing projects. Clin
Pharmacol Ther. 102:688–700. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Bunka M, Wong G, Kim D, Edwards L, Austin
J, Doyle-Waters MM, Gaedigk A and Bryan S: Evaluating treatment
outcomes in pharmacogenomic-guided care for major depression: A
rapid review and meta-analysis. Psychiatry Res.
321(115102)2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Skryabin V, Rozochkin I, Zastrozhin M,
Lauschke V, Franck J, Bryun E and Sychev D: Meta-analysis of
pharmacogenetic clinical decision support systems for the treatment
of major depressive disorder. Pharmacogenomics J. 23:45–49.
2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Binder EB, Salyakina D, Lichtner P,
Wochnik GM, Ising M, Pütz B, Papiol S, Seaman S, Lucae S, Kohli MA,
et al: Polymorphisms in FKBP5 are associated with increased
recurrence of depressive episodes and rapid response to
antidepressant treatment. Nat Genet. 36:1319–1325. 2004.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Zou YF, Wang F, Feng XL, Li WF, Tao JH,
Pan FM, Huang F and Su H: Meta-analysis of FKBP5 gene polymorphisms
association with treatment response in patients with mood
disorders. Neurosci Lett. 484:56–61. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bothos E, Ntoumou E, Kelaidoni K, Roukas
D, Drakoulis N, Papasavva M, Karakostis FA, Moulos P and Karakostis
K: Clinical pharmacogenomics in action: Design, assessment and
implementation of a novel pharmacogenetic panel supporting drug
selection for diseases of the central nervous system (CNS). J
Transl Med. 19(151)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Roukas D, Bothos E, Ntoumou E, Kelaidoni
K, Drakoulis N, Papasavva M, Karakostis FA, Moulos P and Karakostis
K: P.0221 A rapid, concise and robust companion diagnostic pgx test
supporting drug selection for diseases of the central nervous
system. Eur Neuropsychopharmacol. 53 (Suppl 1):S159–S160. 2021.
|
|
14
|
Beunk L, Nijenhuis M, Soree B, de
Boer-Veger NJ, Buunk AM, Guchelaar HJ, Houwink EJF, Risselada A,
Rongen GAPJM, van Schaik RHN, et al: Dutch pharmacogenetics Working
Group (DPWG) guideline for the gene-drug interaction between
CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. Eur J Hum Genet.
32:278–285. 2024.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hall-Flavin DK, Winner JG, Allen JD,
Carhart JM, Proctor B, Snyder KA, Drews MS, Eisterhold LL, Geske J
and Mrazek DA: Utility of integrated pharmacogenomic testing to
support the treatment of major depressive disorder in a psychiatric
outpatient setting. Pharmacogenet Genomics. 23:535–548.
2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Singh AB: Improved antidepressant
remission in major depression via a pharmacokinetic pathway
polygene pharmacogenetic report. Clin Psychopharmacol Neurosci.
13:150–156. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Pérez V, Salavert A, Espadaler J, Tuson M,
Saiz-Ruiz J, Sáez-Navarro C, Bobes J, Baca-García E, Vieta E,
Olivares JM, et al: Efficacy of prospective pharmacogenetic testing
in the treatment of major depressive disorder: Results of a
randomized, double-blind clinical trial. BMC Psychiatry.
17(250)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Bradley P, Shiekh M, Mehra V, Vrbicky K,
Layle S, Olson MC, Maciel A, Cullors A, Garces JA and Lukowiak AA:
Improved efficacy with targeted pharmacogenetic-guided treatment of
patients with depression and anxiety: A randomized clinical trial
demonstrating clinical utility. J Psychiatr Res. 96:100–107.
2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Greden JF, Parikh SV, Rothschild AJ, Thase
ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM,
Shelton RC, et al: Impact of pharmacogenomics on clinical outcomes
in major depressive disorder in the GUIDED trial: A large, patient-
and rater-blinded, randomized, controlled study. J Psychiatr Res.
111:59–67. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tesfamicael KG, Zhao L,
Fernández-Rodríguez R, Adelson DL, Musker M, Polasek TM and Lewis
MD: Efficacy and safety of pharmacogenomic-guided antidepressant
prescribing in patients with depression: An umbrella review and
updated meta-analysis. Front Psychiatry. 15(1276410)2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chatziandreou E and Panagiotou N: EE77
Cost-effectiveness analysis of Pharmacogenetic-guided treatment in
drug resistant depression. Value in Health. 25 (Suppl
1)(S68)2022.
|
|
22
|
Morris SA, Alsaidi AT, Verbyla A, Cruz A,
Macfarlane C, Bauer J and Patel JN: Cost effectiveness of
pharmacogenetic testing for drugs with clinical pharmacogenetics
implementation consortium (CPIC) guidelines: A systematic review.
Clin Pharmacol Ther. 112:1318–1328. 2022.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Carrascal-Laso L, Franco-Martín M,
Marcos-Vadillo E, Ramos-Gallego I, García-Berrocal B, Mayor-Toranzo
E, Sánchez-Iglesias S, Lorenzo C, Sevillano-Jiménez A,
Sánchez-Martín A, et al: Economic impact of the application of a
precision medicine model (5SPM) on psychotic patients.
Pharmgenomics Pers Med. 14:1015–1025. 2021.PubMed/NCBI View Article : Google Scholar
|
